VAXX — Vaxxinity Balance Sheet
0.000.00%
- $0.03m
- -$15.20m
Annual balance sheet for Vaxxinity, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.476 | 31.1 | 145 | 86.8 | 30.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.303 | 0.387 | 0.393 | 0.414 | 0.414 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.44 | 35.7 | 154 | 93.9 | 33.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.16 | 12.2 | 12.4 | 12.5 | 11.1 |
Other Long Term Assets | |||||
Total Assets | 1.59 | 50.1 | 167 | 106 | 44.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 19.9 | 37.2 | 27.5 | 30.9 | 17.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 23.3 | 75 | 38.1 | 44.2 | 30.9 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -21.7 | -24.9 | 129 | 62.2 | 13.4 |
Total Liabilities & Shareholders' Equity | 1.59 | 50.1 | 167 | 106 | 44.3 |
Total Common Shares Outstanding |